MedTrace Logo

To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects

NCT02361034 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-12-15

No results posted yet for this study

Summary

This is a multiple Ascending dose (MAD) study with GRC 27864 in Healthy and Elderly Subjects.

Conditions

  • Healthy

Interventions

DRUG

GRC 27864

DRUG

Placebo

Sponsors & Collaborators

  • Glenmark Pharmaceuticals S.A.

    lead INDUSTRY

Principal Investigators

  • Jim Bush, MBChB, PhD · Medical Director

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02361034 on ClinicalTrials.gov